Glaukos Corporation (GKOS)
Glaukos Corporation (GKOS) Stock Price, Analysis & Data
| Bid | 188.64 |
| Market Cap | 11.11B |
| Revenue (ttm) | 612.84M |
| Net Income (ttm) | -188.05M |
| Beta | 0.76 |
| EPS (ttm) | -3.28 |
| PE Ratio (ttm) | n/a |
| Forward PE | 373.33 |
| P/B (ttm) | 16.24 |
| P/S (ttm) | 18.12 |
| Earnings Date | Oct 28, 2026 |
| Ask | 189.35 |
| Volume | 116,739 |
| Avg. Volume (20D) | 1,026,793 |
| Open | 186.00 |
| Previous Close | 184.15 |
| Day's Range | 186.02 - 189.78 |
| 52-Week Range | 73.16 - 190.00 |
| Analyst | Strong Buy |
| Price Target | 195 (3.29%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infi...
Financial Performance
In 2025, Glaukos's revenue was 507.44M, an increase of 32.33% compared to the previous year's 383.48M. Earnings were -187.69M, an increase of 28.23%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for GKOS stock is "Strong Buy". The 12-month stock price forecast is 195, which is upside of 3.29% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
